Open AccessBrief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction—A Prospective Cohort Study
Author(s) -
Bernard Surial,
Charles Béguelin,
Jean-Philippe Chave,
Marcel Stöckle,
Noémie BoillatBlanco,
T. DocoLecompte,
Enos Bernasconi,
Jan Fehr,
Huldrych F Günthard,
Patrick Schmid,
Laura N Walti,
Hansjakob Furrer,
Andri Rauch,
Gilles Wandeler
Publication year - 2020
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002429
Subject(s) - renal function , medicine , creatinine , tenofovir alafenamide , hazard ratio , confidence interval , prospective cohort study , gastroenterology , cohort , hepatitis b virus , adverse effect , coinfection , hepatitis b , urology , viral load , human immunodeficiency virus (hiv) , immunology , virus , antiretroviral therapy
Whereas tenofovir disoproxil fumarate (TDF) can lead to renal adverse events, tenofovir alafenamide (TAF) has a more favorable renal safety profile. However, the impact of replacing TDF with TAF on renal function and liver parameters among HIV/hepatitis B virus (HBV)-coinfected individuals with renal dysfunction remains unclear.